UMG sign world’s first prescription music agreement with MedRhythms

The first-of-its-kind agreement will see UMG’s back catalogue used to treat the effects of stroke and Alzheimer’s.

Credit: Kristoffer Tripplaar/Alamy

Universal Music Group and digital therapeutics company MedRhythms have signed an agreement for UMG to provide prescription music for patients, with UMG providing access to their impressive back catalogue

The deal is called the first of its kind and will see UMG’s back catalogue used to treat movement deficits caused by neurologic injuries and diseases such as stroke, Alzheimer’s, and multiple sclerosis.

MedRhythms utilises neuroscience that shows music can be used to target specific neural circuitry, which can, in turn, boost neuroplasticity and enhance clinical outcomes. Using a combination of music, software and sensors, MedRhythms claims that their treatments can help restore function lost due to neurologic injuries and disease.

In fact, the US Federal Drug Administration designated MedRhythm’s flagship product, which is designed to aid those living with chronic stroke walking deficits, as a ‘Breakthrough Device’ for its potential to be a more effective treatment for the condition.

UMG will also provide MedRhythms with resources and data gleaned from cultural intelligence and data analytics.

UMG’s Executive Vice President of Digital Strategy Michael Nash noted UMG had played a vital role in music’s importance throughout the wellness industry, telling Music Business Worldwide, “Music has the power to transcend borders, cultures and languages to connect people and elevate the quality of life around the world.

“Now, with MedRhythms, we’re seeing the power of music harnessed to heal. Our innovative collaboration with MedRhythms will enable UMG to help enhance neurologic treatment for patients across the US.”